This session will review the current approaches to managing salivary cancers and the systemic treatment for recurrent or metastatic salivary cancers.
This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, speech language pathologists/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists.
Upon completion of this activity, participants should be able to do the following:
- Identify current approaches to managing salivary cancers.
- Describe novel and systemic treatment for recurrent or metastatic salivary cancers.
Kiran Kakarala, MD, is employed by the University of Kansas Medical Center and has no financial relationships with a commercial interest.
Renata Ferrarotto, MD, is employed by MD Anderson Cancer Center and receives research grants from Ayala Pharmaceutical, EMD Serono, Nanobiotix and Pfizer and serves on the advisory board of Ayala Pharmaceutical and Merck
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 0.75 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.75 Certificate of AttendanceThis activity was designated for 0.75 AMA PRA Category 1 Credit™.